Literature DB >> 18431250

Accumulation of aspartic acid421- and glutamic acid391-cleaved tau in neurofibrillary tangles correlates with progression in Alzheimer disease.

Gustavo Basurto-Islas1, Jose Luna-Muñoz, Angela L Guillozet-Bongaarts, Lester I Binder, Raul Mena, Francisco García-Sierra.   

Abstract

Truncations of tau protein at aspartic acid421 (D421) and glutamic acid391 (E391) residues are associated with neurofibrillary tangles (NFTs) in the brains of Alzheimer disease (AD) patients. Using immunohistochemistry with antibodies to D421- and E391-truncated tau (Tau-C3 and MN423, respectively), we correlated the presence of NFTs composed of these truncated tau proteins with clinical and neuropathologic parameters in 17 AD and 23 non-AD control brains. The densities of NFTs composed of D421- or E391-truncated tau correlated with clinical dementia index and Braak staging in AD. Glutamic acid391 tau truncation was prominent in the entorhinal cortex, whereas D421 truncation was prominent in the subiculum, suggesting that NFTs composed of either D421- or E391-truncated tau may be formed mutually exclusively in these areas. Both truncations were associated with the prevalence of the apolipoprotein E epsilon4 allele. By double labeling, intact tau in NFTs was commonly associated with D421-cleaved tau but not with E391-truncated tau; D421-cleaved tau was never associated with E391-truncated tau. These results indicate that tau is not randomly proteolyzed at different domains, and that proteolysis occurs sequentially from the C-terminus to inner regions of tau in AD progression. Identification of NFTs composed of tau at different stages of truncation may facilitate assessment of neurofibrillary pathology in AD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18431250      PMCID: PMC4699801          DOI: 10.1097/NEN.0b013e31817275c7

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  90 in total

1.  Expression and distribution of carboxypeptidase B in the hippocampal subregions of normal and Alzheimer's disease brain.

Authors:  Henrietta Papp; I Török; A Matsumoto; T Enomoto; S Matsuyama; P Kása
Journal:  Acta Biol Hung       Date:  2003

2.  Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer's disease.

Authors:  Peleg M Horowitz; Kristina R Patterson; Angela L Guillozet-Bongaarts; Matthew R Reynolds; Christopher A Carroll; Susan T Weintraub; David A Bennett; Vincent L Cryns; Robert W Berry; Lester I Binder
Journal:  J Neurosci       Date:  2004-09-08       Impact factor: 6.167

3.  An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde".

Authors:  A Alzheimer; R A Stelzmann; H N Schnitzlein; F R Murtagh
Journal:  Clin Anat       Date:  1995       Impact factor: 2.414

4.  Degradation of tau protein by puromycin-sensitive aminopeptidase in vitro.

Authors:  Soma Sengupta; Peleg M Horowitz; Stanislav L Karsten; George R Jackson; Daniel H Geschwind; Yifan Fu; Robert W Berry; Lester I Binder
Journal:  Biochemistry       Date:  2006-12-19       Impact factor: 3.162

5.  Downregulation of oxidative phosphorylation in Alzheimer disease: loss of cytochrome oxidase subunit mRNA in the hippocampus and entorhinal cortex.

Authors:  K Chandrasekaran; K Hatanpää; D R Brady; J Stoll; S I Rapoport
Journal:  Brain Res       Date:  1998-06-15       Impact factor: 3.252

6.  Sequential changes of tau-site-specific phosphorylation during development of paired helical filaments.

Authors:  T Kimura; T Ono; J Takamatsu; H Yamamoto; K Ikegami; A Kondo; M Hasegawa; Y Ihara; E Miyamoto; T Miyakawa
Journal:  Dementia       Date:  1996 Jul-Aug

7.  Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology.

Authors:  Robert A Rissman; Wayne W Poon; Mathew Blurton-Jones; Salvatore Oddo; Reidun Torp; Michael P Vitek; Frank M LaFerla; Troy T Rohn; Carl W Cotman
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

8.  Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study.

Authors:  Kathryn P Riley; David A Snowdon; William R Markesbery
Journal:  Ann Neurol       Date:  2002-05       Impact factor: 10.422

9.  Neuropathological definition of Alzheimer disease: multivariate analyses in the morphometric distinction between Alzheimer dementia and normal aging.

Authors:  M J Ball; S Griffin-Brooks; J A MacGregor; B Nagy; E Ojalvo-Rose; P H Fewster
Journal:  Alzheimer Dis Assoc Disord       Date:  1988       Impact factor: 2.703

10.  A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads.

Authors:  E Braak; H Braak; E M Mandelkow
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

View more
  54 in total

Review 1.  Targeting tau protein in Alzheimer's disease.

Authors:  Cheng-Xin Gong; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

2.  Caspase-Cleaved Tau Impairs Mitochondrial Dynamics in Alzheimer's Disease.

Authors:  María José Pérez; Katiana Vergara-Pulgar; Claudia Jara; Fabian Cabezas-Opazo; Rodrigo A Quintanilla
Journal:  Mol Neurobiol       Date:  2017-01-13       Impact factor: 5.590

3.  Truncation of tau at E391 promotes early pathologic changes in transgenic mice.

Authors:  Pamela J McMillan; Brian C Kraemer; Linda Robinson; James B Leverenz; Murray Raskind; Gerard Schellenberg
Journal:  J Neuropathol Exp Neurol       Date:  2011-11       Impact factor: 3.685

Review 4.  Cellular factors modulating the mechanism of tau protein aggregation.

Authors:  Sarah N Fontaine; Jonathan J Sabbagh; Jeremy Baker; Carlos R Martinez-Licha; April Darling; Chad A Dickey
Journal:  Cell Mol Life Sci       Date:  2015-02-11       Impact factor: 9.261

Review 5.  Therapeutic Strategies for Restoring Tau Homeostasis.

Authors:  Zapporah T Young; Sue Ann Mok; Jason E Gestwicki
Journal:  Cold Spring Harb Perspect Med       Date:  2018-01-02       Impact factor: 6.915

6.  Caspase activation precedes and leads to tangles.

Authors:  Alix de Calignon; Leora M Fox; Rose Pitstick; George A Carlson; Brian J Bacskai; Tara L Spires-Jones; Bradley T Hyman
Journal:  Nature       Date:  2010-03-31       Impact factor: 49.962

7.  BRI2 ectodomain affects Aβ42 fibrillation and tau truncation in human neuroblastoma cells.

Authors:  M Del Campo; C R Oliveira; W Scheper; R Zwart; C Korth; A Müller-Schiffmann; G Kostallas; H Biverstal; J Presto; J Johansson; J J Hoozemans; C F Pereira; C E Teunissen
Journal:  Cell Mol Life Sci       Date:  2014-10-22       Impact factor: 9.261

Review 8.  Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases.

Authors:  Eugene M Cilento; Lorrain Jin; Tessandra Stewart; Min Shi; Lifu Sheng; Jing Zhang
Journal:  J Neurochem       Date:  2019-01-31       Impact factor: 5.372

Review 9.  Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.

Authors:  Mansi R Khanna; Jane Kovalevich; Virginia M-Y Lee; John Q Trojanowski; Kurt R Brunden
Journal:  Alzheimers Dement       Date:  2016-10       Impact factor: 21.566

10.  A unique tau conformation generated by an acetylation-mimic substitution modulates P301S-dependent tau pathology and hyperphosphorylation.

Authors:  Deepa Ajit; Hanna Trzeciakiewicz; Jui-Heng Tseng; Connor M Wander; Youjun Chen; Aditi Ajit; Diamond P King; Todd J Cohen
Journal:  J Biol Chem       Date:  2019-09-22       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.